Pacific Biometrics, Inc. Retains RJ Falkner & Company, Inc. as Investor Relations Counsel
Seattle, Washington, September 8, 2008 - Pacific Biometrics, Inc. (PBI) (OTCBB: PBME)a leading provider of specialty medical laboratory and biomarker assay development and testing services, today announced that it has retained RJ Falkner & Company to develop and implement a comprehensive investor relations program for the Company.
RJ Falkner & Company, Inc. is an investment research and financial communications firm that seeks out undervalued small-cap companies with the potential to outperform the overall stock market on an intermediate- and long-term basis. Its research analysts work with the managements of such companies to broaden their exposure within the investment community and expand the level of interest among investment professionals and high-net-worth individual investors. Additional information on RJ Falkner & Company, Inc. is available on the Internet at www.rjfalkner.com.
"We selected RJ Falkner & Company as our investor relations firm because of its expertise in shareholder communications and the relationships that its research analysts have developed within the investment community during the past 39 years," stated Ron Helm, Chairman and Chief Executive Officer of Pacific Biometrics, Inc.
"We are excited to be selected to provide a full range of investor relations services to Pacific Biometrics, Inc.," commented R. Jerry Falkner, CFA, President of RJ Falkner & Company, Inc. "The Company has developed an outstanding reputation for providing specialty laboratory services to leading pharmaceutical, biotech and diagnostic companies involved in clinical trials of new drugs, particularly in the areas of cardiovascular disease, diabetes, osteoporosis, and arthritis. Demographic trends in the U.S. should support continued growth of pharmaceutical development in these areas. In addition, expanding interest in 'targeted therapeutics' throughout the medical industry should increase demand for Pacific Biometrics' biomarker assay services in coming years."
The agreement between Pacific Biometrics, Inc. and RJ Falkner & Company covers one year and provides for assistance in investor relations, press release development, the preparation of independent analyses and research reports, and other related services of benefit to Pacific Biometrics, Inc. Any forecasts, projections and/or conclusions contained in research reports published by RJ Falkner & Company will be independently prepared by RJ Falkner & Company, unless otherwise stated, and will not be endorsed by the management of Pacific Biomarkers, Inc.
About Pacific Biometrics, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biomarkers, Inc., incorporated February 1, 2008 as a wholly owned subsidiary of Pacific Biometrics, Inc., focuses specifically on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.
For more information about Pacific Biometrics, visit the Company's web site at www.pacbio.com. The Company is headquartered in Seattle, Washington and its common stock trades on the OTC Bulletin Board under the symbol "PBME."
Contact:
Pacific Biometrics, Inc.
Ron Helm, Chairman and CEO
(206) 298-0068
or
R. Jerry Falkner CFA
RJ Falkner & Company, Inc.
Investor Relations Counsel
(800) 377-9893
email at info@rjfalkner.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including, but not limited to, the growth in revenues and backlog that may result from established and new services, our strategic planning and business development plans, impacts on our financial results, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2007 and our Form 10-QSB for the quarters ended September 30, 2007, December 31, 2007, and March 31, 2008).
Home | About PBI | Investors | Lab Services | News/Publications | Test Menu | Contact | Privacy Policy
